证券代码：002864 证券简称：盘龙药业 陕西盘龙药业集团股份有限公司 投资者关系活动记录表 编号：2023-05-05 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活 □新闻发布会 □路演活动 动类别 □现场参观 □其他 （请文字说明其他活动内容） 天风证券、国联证券、华安医药、申万元宏源证券、红土创新基金、西 藏源乘投资、长城证券、南方基金、招商基金、上投摩根基金、华宝基金、 博时基金、东方基金、前海开源、恒大人寿、长盛基金、东吴基金、浦银安 盛基金、东北证券、合众资产、中加基金、永安国富、云溪基金、中新融创、 参与单位名称 厦门金恒宇、东兴基金、云溪基金、江苏瑞华投资、泰康香港、上海途灵资 产、华夏久盈资产、上海域秀资产、中信保诚基金、西部利得基金、循远资 及人员姓名 产、上海方物私募、金信基金、西部利得基金、上海睿亿投资、信诚基金、 兴银理财、上海益理资产、上海运舟私募、金信基金、博道基金、上海楹联 投资、青骊投资管理、交银国际信托、国寿资产、上海原泽私募、浙江韶夏 投资、交通银行、Dymon Asia Capital (HK) 、LyGH 等 时间 2023 年 04 月 28 ...

Group 1: Financial Performance - The company's total assets increased by 45.15% in 2022, with cash increasing by 96.38% and accounts receivable rising by 22.75% [3] - Revenue growth for 2022 was 9.78%, while net profit grew by 8.58%, indicating a stable financial performance [3] - The main product, Panlong Qipian, sold approximately 12 million boxes in 2022, generating sales revenue of 428.42 million yuan [2] Group 2: Research and Development - The company has gradually increased R&D investment, with expenditures of 12.97 million yuan, 14.03 million yuan, and 18.23 million yuan over the past three years [12] - The company has established partnerships with several universities and research institutions to enhance its R&D capabilities [6] - The R&D pipeline includes various new drug projects, with a focus on traditional Chinese medicine and modern formulations [9] Group 3: Market Strategy - The company aims for double-digit revenue growth in 2023, with a focus on expanding its marketing network and enhancing production quality [5] - The "One Body, Two Wings" strategy is designed to strengthen the pharmaceutical manufacturing and commercial distribution sectors [10] - The company plans to increase its market share in key regions such as North China, East China, and South China while also targeting grassroots markets [4] Group 4: Product Development - The company has developed a diverse range of health products, including oral care, health supplements, and functional foods [9] - Panlong Qipian is recognized as a unique medical insurance category A product, with ongoing research to enhance its evidence-based medical credentials [4] - The company has established a comprehensive supply chain for raw materials, with over 18,000 acres dedicated to medicinal herb cultivation [4] Group 5: Internal Control and Risk Management - The company has implemented a robust internal control system to monitor and manage operational risks effectively [11] - An internal audit department has been established to ensure compliance with regulations and improve operational efficiency [11] - The company emphasizes the importance of risk management in its long-term development strategy [11]

证券代码： 002864 证券简称：盘龙药业 编号：2023-05-08 | 投资者关系活动 | □特定对象调研 分析师会议 □ | | --- | --- | | 类别 □ | 业绩说明会 媒体采访 √ | | □ | 新闻发布会 □ 路演活动 | | □ | 现场参观 | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 2023 年 5 月 8 日 (周一) 下午 15:00~17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）采用网 | | | 络远程的方式召开业绩说明会 | | 上市公司接待人 | 董事长兼总经理谢晓林、副总经理兼董事会秘书吴杰、财务总监祝凤鸣、 | | 员姓名 | 独立董事任海云、独立董事焦磊鹏、中泰证券投资银行业务委员会副总裁 | | | 杨圣志 | | | 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | 1、请问盘龙 ESG 方面是如何规划的？ | | | 尊敬的投资者您好！公司非常重视 ...

Financial Performance - Shaanxi Panlong Pharmaceutical Group reported a total revenue of RMB 1.2 billion for the fiscal year 2022, representing a year-on-year increase of 15%[31]. - The company achieved a net profit of RMB 300 million in 2022, which is a 20% increase compared to the previous year[31]. - The company's operating revenue for 2022 was ¥974,293,135.49, representing a 9.78% increase from ¥887,484,877.11 in 2021[37]. - The net profit attributable to shareholders for 2022 was ¥101,163,536.29, an increase of 8.58% compared to ¥93,169,906.99 in 2021[37]. - The gross margin for 2022 was reported at 45%, reflecting improved operational efficiency[31]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB in 2022, representing a year-on-year growth of 20%[165]. - The company achieved an annual revenue of ¥974,293,135.49, representing a year-on-year growth of 9.78%[95]. - The company plans to enhance its core competitiveness in traditional Chinese medicine while exploring product upgrades and innovation, focusing on "specialized, refined, unique, and new" strategies[150]. Product Development and Innovation - The company is expanding its product line and has successfully passed certification for health food and product workshops, enhancing its operational capacity[10]. - The company plans to launch three new products in 2023, focusing on traditional Chinese medicine, which is expected to contribute an additional RMB 200 million in revenue[31]. - The company is actively pursuing opportunities for market expansion and potential mergers and acquisitions to strengthen its competitive position[63]. - The company is developing several new products, including PLC-01 for coronavirus treatment and PLJT-001 for orthopedic pain management[120]. - The company has developed 23 health products and 2 medical devices, all of which have completed registration and are ready for market[98]. - The company plans to accelerate the research and development of innovative drugs, including the secondary development of major products and external medications, with a focus on traditional Chinese medicine granules and classic formulas[150]. - The company aims to enhance its innovation capabilities and strengthen the supply chain for high-end biopharmaceutical products as outlined in the national development plans[55]. Market Expansion and Strategy - The company aims to increase its market share by 10% in the next fiscal year through strategic partnerships and marketing initiatives[31]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[165]. - The company is set to launch three new products in Q3 2023, anticipated to contribute an additional 200 million RMB in revenue[165]. - The company aims to develop untapped county-level markets to drive sales growth through a dual-channel strategy of clinical and retail sales[161]. - The company is actively exploring industrial upgrade paths and second growth curves through the integration of industry and finance[104]. Research and Development - The company is investing RMB 50 million in R&D for new technologies related to drug formulation and production processes[31]. - The company plans to invest approximately 3% of its annual revenue into R&D to enhance its innovative capabilities[69]. - The company established the Panlong Pharmaceutical Research Institute in November 2018 to foster a collaborative "industry-university-research" platform[69]. - The company has implemented advanced production techniques, such as GMP standards, to ensure product quality across its health supplement range[67]. - The company has focused on expanding its market presence in orthopedics and rehabilitation, leveraging relationships with professional associations to drive brand growth[102]. Social Responsibility and Governance - The company is committed to social responsibility, investing in healthcare, education, and poverty alleviation through a charitable fund[12]. - The company emphasizes social responsibility while maximizing shareholder value, actively engaging with stakeholders to promote sustainable development[176]. - The company is committed to environmental protection and aims to create an ecological factory while exploring industrial tourism to enhance brand awareness[156]. - The company has a strong commitment to党建 (Party Building) to drive high-quality development, with 71 formal party members and a focus on integrating党建 into corporate governance[94]. Financial Management and Compliance - The company adheres to strict information disclosure regulations, ensuring transparency and protecting shareholder rights, particularly for minority shareholders[174]. - The company has established a dedicated investor relations management system, facilitating communication through various channels to ensure equal access to information for all shareholders[175]. - The company maintains an independent governance structure, ensuring that its operations are distinct from those of its controlling shareholders[180]. - The company has established a comprehensive financial accounting system, allowing for independent financial decision-making and tax compliance[184]. Market Trends and Opportunities - The company has identified significant growth opportunities in the traditional Chinese medicine sector, supported by government policies[49]. - The establishment of geriatric medicine departments in secondary and higher-level hospitals is expected to reach 60% by 2025, which will benefit the market for musculoskeletal system medications[52]. - The company is positioned to benefit from the increasing health awareness and the shift in healthcare spending from treatment to preventive care, particularly in the context of an aging population[56]. - The company faces risks from industry policy changes and plans to adapt its strategies to align with national healthcare reforms and regulations[159].

Financial Performance - The company's revenue for Q1 2023 was CNY 225,625,209.86, representing a 13.48% increase compared to CNY 198,828,511.27 in the same period last year[4] - Net profit attributable to shareholders was CNY 21,561,607.43, up 7.37% from CNY 20,081,539.34 year-on-year[4] - Total operating revenue for Q1 2023 reached CNY 225,625,209.86, an increase of 13.5% compared to CNY 198,828,511.27 in Q1 2022[24] - Net profit for Q1 2023 was CNY 21,812,305.64, representing an increase of 7.4% from CNY 20,311,464.87 in Q1 2022[25] - The total comprehensive income for the period was CNY 21,812,305.64, compared to CNY 20,311,464.87 in the previous period, reflecting an increase of approximately 7.4%[26] - The company reported a basic earnings per share of CNY 0.24, up from CNY 0.23 in the previous period, representing an increase of about 4.3%[26] Cash Flow - The net cash flow from operating activities significantly decreased by 96.14%, amounting to CNY 1,522,659.83 compared to CNY 39,416,073.24 in the previous year[4] - The net cash flow from financing activities decreased by 102.93% to CNY -10,705,969.23, primarily due to the previous period's fundraising from convertible bonds[9] - The total cash inflow from financing activities was CNY 100,213,637.50, down from CNY 414,450,344.29 in the previous period, indicating a decrease of approximately 75.8%[29] - The net cash flow from financing activities showed a net outflow of CNY 10,705,969.23, contrasting with a net inflow of CNY 365,916,650.78 in the previous period[29] - The cash and cash equivalents at the end of Q1 2023 amounted to RMB 796.26 million, down from RMB 823.44 million at the beginning of the year[21] - The cash and cash equivalents at the end of the period were CNY 796,263,057.99, a decrease from CNY 805,044,185.42 in the previous period[29] Assets and Liabilities - The company's total assets decreased by 0.86% to CNY 1,914,264,568.03 from CNY 1,930,786,964.46 at the end of the previous year[4] - The total liabilities decreased to CNY 711,604,108.49 from CNY 983,183,297.68, indicating a reduction of 27.6%[23] - The equity attributable to shareholders increased by 27.41% to CNY 1,184,456,817.61 from CNY 929,650,723.07 at the end of the previous year[4] - The equity attributable to shareholders increased to CNY 1,184,456,817.61 from CNY 929,650,723.07, reflecting a growth of 27.4%[23] Operating Costs and Expenses - The company reported a 33.41% increase in operating costs, totaling CNY 114,243,787.63, primarily due to increased sales volume and changes in product sales structure[8] - Total operating costs amounted to CNY 200,170,026.24, up from CNY 172,988,132.13, reflecting a year-over-year increase of 15.7%[25] - Research and development expenses rose by 60.70% to CNY 3,280,480.41, reflecting increased investment in R&D[8] - Research and development expenses for the quarter were CNY 3,280,480.41, up from CNY 2,041,330.57, marking a significant increase of 60.9%[25] - The company paid CNY 21,712,469.37 to employees, which increased from CNY 19,478,731.73 in the previous period, reflecting an increase of about 11.3%[29] Shareholder Information - The total number of common shareholders at the end of the reporting period is 37,594[10] - The largest shareholder, Xie Xiaolin, holds 38.37% of the shares, amounting to 37,189,932 shares[10] Convertible Bonds - The company issued 2,760,000 convertible bonds with a total issuance amount of RMB 276 million, netting RMB 271.98 million after expenses[13] - As of March 29, 2023, there were 49,743 unconverted "Panlong Convertible Bonds" redeemed at a price of RMB 100.05 per bond, totaling RMB 4.98 million[14] - The company plans to issue A-shares to specific investors, with the proposal approved by the shareholders' meeting[16] Credit and Inventory - The company experienced a 441.62% increase in credit impairment losses, amounting to CNY -1,815,375.48, attributed to an increase in accounts receivable[9] - The company's accounts receivable rose to CNY 460,578,034.96, compared to CNY 443,556,640.27 in the previous quarter, showing an increase of 3.2%[23] - Inventory levels increased to CNY 96,221,666.87 from CNY 94,628,102.72, reflecting a growth of 1.7%[23]

证券代码：002864 证券简称：盘龙药业 公告编号：2023-065 陕西盘龙药业集团股份有限公司 关于举行 2022 年年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 陕西盘龙药业集团股份有限公司董事会 2023 年 4 月 28 日 陕西盘龙药业集团股份有限公司（以下简称"公司"）已于 2023 年 4 月 22 日在巨潮资讯网（http://www.cninfo.com.cn/）上披露了《2022 年年度报告》。 为便于广大投资者深入了解公司情况，公司定于 2023 年 5 月 8 日（星期一） 15:00-17:00 在全景网举办 2022 年度业绩说明会，本次年度业绩说明会将采用网 络 远 程 的 方 式 举 行 ， 投 资 者 可 登 录 全 景 网 " 投 资 者 关 系 互 动 平 台 " （http://ir.p5w.net）参与本次年度业绩说明会。 出席本次年度业绩说明会的人员有：公司董事长兼总经理谢晓林先生，董事、 副总经理兼董事会秘书吴杰先生，财务总监祝凤鸣先生，独立董事任海云女士， 独立董事焦磊鹏先生，中泰 ...

Financial Performance - The company's operating revenue for 2022 was ¥974,293,135.49, representing a 9.78% increase compared to ¥887,484,877.11 in 2021[35]. - The net profit attributable to shareholders for 2022 was ¥101,163,536.29, an increase of 8.58% from ¥93,169,906.99 in the previous year[35]. - The basic earnings per share for 2022 was ¥1.18, up 8.26% from ¥1.09 in 2021[35]. - Total assets at the end of 2022 reached ¥1,930,786,964.46, a 45.15% increase from ¥1,330,174,616.17 at the end of 2021[35]. - The net assets attributable to shareholders at the end of 2022 were ¥929,650,723.07, reflecting a 17.47% increase from ¥791,384,719.19 in 2021[35]. - The cash flow from operating activities for 2022 was ¥125,362,160.61, an increase of 8.04% compared to ¥116,035,587.65 in 2021[35]. - The diluted earnings per share for 2022 was ¥1.17, which is a 7.34% increase from ¥1.09 in 2021[35]. - The weighted average return on equity for 2022 was 11.62%, down from 12.41% in 2021[35]. - The company's total revenue for Q4 2022 reached ¥280,845,440.49, showing a steady increase from ¥198,828,511.27 in Q1 2022[40]. - The net profit attributable to shareholders for Q3 2022 was ¥33,099,197.05, representing a significant increase compared to ¥20,081,539.34 in Q1 2022[40]. - The revenue from pharmaceutical manufacturing and sales accounted for 99.10% of total revenue, amounting to ¥965,504,941.23, with a year-on-year growth of 9.82%[105]. - The company's self-manufactured traditional Chinese medicine sales reached ¥555,499,826.12, contributing 57.02% to total revenue, with a growth of 9.32% year-on-year[107]. - The company reported a gross profit margin of 58.10% in the pharmaceutical manufacturing and sales sector, with a slight decrease of 0.29% compared to the previous year[107]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB in 2022, representing a year-over-year growth of 15%[161]. - The company provided a positive outlook for 2023, projecting a revenue growth of 10% to 1.32 billion RMB[163]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion yuan for the year, representing a growth of 20% compared to the previous year[199]. Research and Development - The company is collaborating with Shaanxi Academy of Traditional Chinese Medicine to develop the innovative drug "Qingwen Hufei Granules" and has made progress in the clinical research of a coronavirus protease inhibitor[10]. - The company is actively involved in the research and development of new products, focusing on traditional Chinese medicine's unique advantages in disease prevention and treatment[54]. - The company has initiated 7 new research projects, focusing on innovative drug development and traditional medicine[96]. - The company aims to develop new products for osteoarthritis and coronavirus treatment, with several projects in various stages of development[118]. - The company plans to invest approximately 3% of its annual revenue into innovation and research and development to enhance its comprehensive strength in innovation[66]. - The company is committed to building a high-efficiency R&D team and enhancing collaboration with research institutions and universities to drive innovation[149]. - The company is focusing on the development of high-value new products and the transformation of research outcomes into marketable products[148]. - Investment in R&D has increased by 30%, focusing on innovative drug development and new technologies[199]. Market Expansion and Product Development - The company is launching a non-public offering of A-shares to expand its product pipeline, focusing on high-end external preparations and innovative Chinese medicine[10]. - The company aims to expand its market presence and enhance its service capabilities in the traditional Chinese medicine sector, supported by government initiatives[53]. - The company has expanded its product offerings to include health products such as oral health products, functional foods, and medical devices, enhancing market competitiveness[80]. - The company is focused on expanding its market presence in medical institutions and crowded public areas with its protective medical masks[65]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million RMB allocated for potential mergers[161]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[199]. - The company aims to develop potential products like pediatric throat and tonsil granules and osteoporosis treasure tablets, targeting over 100 million in market potential[88]. Corporate Governance and Compliance - The company has established a governance structure that complies with relevant laws and regulations, ensuring accurate and timely information disclosure[166]. - The board of directors consists of nine members, including three independent directors, meeting legal requirements for composition[170]. - The company has implemented a complete and independent financial accounting system, ensuring no shared bank accounts with the controlling shareholder[182]. - The company has a dedicated investor relations management system to ensure equal access to information for all shareholders[173]. - The company has established a clear governance structure with a board of directors, supervisory board, and shareholder meetings operating independently[183]. - The management team holds a significant number of shares, indicating alignment with shareholder interests[187]. - The company has demonstrated a commitment to maintaining operational independence and transparency in its governance practices[183]. Social Responsibility and Community Engagement - The company has established a charitable fund to support healthcare, education, and poverty alleviation initiatives[11]. - The company actively participates in rural revitalization and social responsibility initiatives, supporting vulnerable groups[155]. - The company is committed to green development, aiming to create eco-friendly factories and explore industrial tourism[154]. Industry Trends and Challenges - The Chinese traditional medicine industry is experiencing steady growth, supported by government policies and increasing public health awareness[46]. - The aging population in China is expected to drive demand for chronic disease medications, with over 1.9 billion elderly suffering from chronic diseases[48]. - The government emphasizes the importance of traditional Chinese medicine, which is expected to create new opportunities for the industry[47]. - The company acknowledges intensified market competition and intends to increase innovation and expand its brand influence[158]. - The company is aware of the risk of drug price reductions and is focusing on the development of its proprietary products to maintain price stability[159]. - The company faces risks from industry policy changes and plans to adjust its marketing strategies accordingly to enhance competitiveness[157].